Aptose Biosciences (APTO) to Offer Common Stock

Aptose Biosciences Inc. (NASDAQ: APTO) today announced that it has commenced an underwritten public offering of its common shares (the “Offering”). In addition, Aptose intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the common shares offered in the Offering. The Offering is subject to market and other conditions, and there can be no assurance as to whether or when the Offering may be completed, or as to the actual size or terms of the offering. All of the common shares to be sold in the proposed offering will be sold by the Company.

Aptose intends to use the net proceeds of the Offering to (i) accelerate and expand clinical trials for CG-806; (ii) accelerate and expand clinical trials for APTO-253; (iii) acquire and fund (including through partnerships and in-licensing) additional clinical assets; and (iv) for working capital and general corporate purposes.

Piper Sandler & Co. is acting as the sole active book-running manager for the Offering.

You May Also Be Interested In

• ASP Isotopes unit to merge with ENDRA Life Sciences in $50M deal
• Firefox Gold closes $6.7M private placement final tranche
• Quantum Space names Adarsh Parekh as CFO ahead of public listing